SEBIVO

This brand name is authorized in Estonia, Hong Kong, Lithuania, Poland, Romania, Singapore

Active ingredients

The drug SEBIVO contains one active pharmaceutical ingredient (API):

1 Telbivudine UNII 2OC4HKD3SF - TELBIVUDINE

Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase. It is efficiently phosphorylated by cellular kinases to the active triphosphate form. Incorporation of telbivudine-5'-triphosphate into viral DNA causes DNA chain termination, resulting in inhibition of HBV replication. Read about Telbivudine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SEBIVO Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AF11	Telbivudine	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
Discover more medicines within J05AF11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1294781, 1367940, 1437836
Country: HK	Department of Health Drug Office	Identifier(s): 55624
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1030594, 1030595, 1036163
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100206276, 100219422
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64471001, W64471002
Country: SG	Health Sciences Authority	Identifier(s): 13304P